Development of a Disease Progression Model for Leucine‐Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial Designs-Reference-Cited by-同舟云学术

Development of a Disease Progression Model for Leucine‐Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial Designs

Published:2019-12-05 Issue:3 Volume:107 Page:553-562
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Ahamadi Malidi¹,Conrado Daniela J²,Macha Sreeraj¹,Sinha Vikram¹,Stone Julie¹,Burton Jackson²,Nicholas Timothy³,Gallagher Jill⁴,Dexter David⁴,Bani Massimo⁵,Boroojerdi Babak⁵,Smit Hans⁵,Weidemann Jonas⁶,Chen Chao⁷,Yang Minhua⁸,Maciuca Romeo⁹,Lawson Rachael¹⁰,Burn David¹⁰,Marek Kenneth¹¹,Venuto Charles¹²,Stafford Bob²,Akalu Mussie²,Stephenson Diane²,Romero Klaus²,

Affiliation:

1. Merck & Co., Inc. Kenilworth New Jersey USA

2. Critical Path Institute Tucson Arizona USA

3. Pfizer Groton Connecticut USA

4. Parkinson's UK London UK

5. UCB Brussels Belgium

6. Lundbeck Copenhagen Denmark

7. GSK UK Uxbridge UK

8. Biogen Cambridge Massachusetts USA

9. Denali Therapeutics Inc. San Francisco California USA

10. Incidence of Cognitive Impairment in Cohorts with Longitudinal Evaluation in Parkinson's Disease Newcastle University Newcastle upon Tyne UK

11. Institute of Neurodegenerative Diseases New Haven Connecticut USA